Here’s a roundup of companies announcing new distribution deals.
- Caliper and HistoRx collaborate on biomarkers
Caliper Life Sciences Inc. (NSDQ:CALP) and HistoRx Inc. announced a collaboration to co-develop a new generation of tissue-based imaging and analysis solutions, based on immuno-fluorescence, that will deliver accurate, quantitative, and reproducible measurements of proteins in tissue samples. The collaboration will enable researchers to leverage the combined imaging and analysis power of Caliper’s Vectra, an automated multiplexed tissue imaging platform, and AQUA technology, HistoRx’s proprietary image analysis system, to provide an integrated platform to advance the identification and validation of new drug targets and improve assessment of drug response.
- STAAR enters Australian distribution deal with Ellex
STAAR Surgical Co. (NSDQ:STAA) announced that it has entered into an agreement with Ellex Australia (ASX:ELX) for the exclusive distribution of STAAR intraocular lenses in Australia. Ellex, a leading ophthalmic manufacturer and distributor that is publicly traded in Australia, will market STAAR’s Visian ICL line of refractive lenses, STAAR’s intraocular lenses for cataract patients and related products. STAAR has previously distributed its products in the region through ConceptVision Australia, a wholly owned subsidiary, which is being closed. During 2010 STAAR generated $1.7 million in sales from the region through a direct team of five employees and generated about $200,000 in net income.
- Philips hires DMS Health for nuclear medicine equipment service in the upper midwest
DMS Health Technologies, a distributor for Philips Healthcare, announced the expansion of Philips Nuclear Medicine (PET, PET/CT, Spect, PROS) equipment service support in its defined upper Midwest territory. In August 2010, DMS Health Technologies added Philips Nuclear Medicine equipment to its sales portfolio.
- Fenwal, Golden Meditech ink deal to form joint venture in China
Fenwal Inc. of Lake Zurich, Illinois, and Golden Meditech Holdings Ltd. (stock code: 801.HK; 910801.TW) of Hong Kong announced they have entered into a definitive agreement to form a joint venture in China that will sell advanced products and technologies for blood collection, storage and transfusion. The joint venture is expected to be formed later this year after receiving customary commercial and regulatory approvals.
- Fibrocell announces collaboration with UCLA on fibroblast research
Fibrocell Science Inc. (OTC:FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced that it has entered into a scientific collaboration with University of California, Los Angeles to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity.
- Roche and RainDance join up for targeted sequencing to for ADME research
RainDance Technologies Inc., and 454 Life Sciences, a Roche Company, announced collaboration for the development and commercialization of a targeted next-generation sequencing (NGS) solution for simple and cost-effective investigation of drug absorption, distribution, metabolism, and excretion (ADME). As part of the collaboration, RainDance and 454 Life Sciences plan to commercially launch a core ADME gene screening research panel that will address one of the large unmet research needs in academic, pharmaceutical and biotechnology markets. The panel will be made available on both the 454 Life Sciences’ GS Junior and GS FLX Systems. On the same day it announced its deal with Roche, RainDance said it expanded its collaboration on ADME analysis with Ambry Genetics.
- Varian and ScandiDos AB announce distribution deal
Varian Medical Systems and ScandiDos AB hereby announce that the companies have signed a non-exclusive distributor agreement. The agreement covers the ScandiDos Delta4PT pre-treatment verification system, for use with Varian’s RapidArc radiotherapy technology, the TrueBeam™ system, and Varian’s technology for IMRT. The agreement allows Varian and its affiliates world-wide to offer Delta4PT to their customers, providing additional solutions for fast and accurate verification of complex radiation therapy technologies.